Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Tax Provisions (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Tax Provisions readings, the most recent being $10.1 million for Q1 2026.

  • On a quarterly basis, Tax Provisions rose 43.6% to $10.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $32.9 million, a 209.48% increase, with the full-year FY2025 number at $29.9 million, up 324.13% from a year prior.
  • Tax Provisions hit $10.1 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $9.1 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $11.0 million in Q4 2023 to a low of -$177.4 million in Q3 2022.
  • Median Tax Provisions over the past 5 years was $5.0 million (2025), compared with a mean of -$7.2 million.
  • The widest YoY moves for Tax Provisions: up 816.67% in 2022, down 150203.39% in 2022.
  • Kiniksa Pharmaceuticals International's Tax Provisions stood at $2.4 million in 2022, then soared by 362.23% to $11.0 million in 2023, then crashed by 173.55% to -$8.1 million in 2024, then surged by 212.1% to $9.1 million in 2025, then grew by 11.23% to $10.1 million in 2026.
  • The last three reported values for Tax Provisions were $10.1 million (Q1 2026), $9.1 million (Q4 2025), and $8.7 million (Q3 2025) per Business Quant data.